Evidence map›Paper›PMID 42014929›Full record

ArticleJournal of medicinal chemistry2026

Peptidomimetic α,β-Unsaturated Ethyl Esters Are Irreversible Inactivators of Human Cathepsin L and Are Potent Inhibitors of SARS-CoV-2 in Cellular Models of COVID-19.

Vivek Kumar, Aleksandra Drelich, Bala C Chenna, Andrew Rademacher, Alexandria M Kemp, Anthony C Bishop, Panatda Saenkham-Huntsinger, Elena Scott, A Joshua Wand, Arthur Laganowsky and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Vivek KumarDepartment of Biochemistry and Biophysics, Texas A&M University, 301 Old Main Drive, College Station, Texas 77843, United States.
Aleksandra DrelichDepartment of Microbiology & Immunology Centers for Biodefense and Emerging Diseases, The University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, Texas 77555, United States.
Bala C ChennaDepartment of Biochemistry and Biophysics, Texas A&M University, 301 Old Main Drive, College Station, Texas 77843, United States.ORCID 0000-0002-2660-5302
Andrew RademacherDepartment of Biochemistry and Biophysics, Texas A&M University, 301 Old Main Drive, College Station, Texas 77843, United States.
Alexandria M KempDepartment of Biochemistry and Biophysics, Texas A&M University, 301 Old Main Drive, College Station, Texas 77843, United States.
Anthony C BishopDepartment of Biochemistry and Biophysics, Texas A&M University, 301 Old Main Drive, College Station, Texas 77843, United States.
Panatda Saenkham-HuntsingerDepartment of Microbiology & Immunology Centers for Biodefense and Emerging Diseases, The University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, Texas 77555, United States.
Elena ScottDepartment of Chemistry, Texas A&M University, 580 Ross St. College Station, Texas 77843-3255, United States.
A Joshua WandDepartment of Biochemistry and Biophysics, Texas A&M University, 301 Old Main Drive, College Station, Texas 77843, United States.
Arthur LaganowskyDepartment of Chemistry, Texas A&M University, 580 Ross St. College Station, Texas 77843-3255, United States.ORCID 0000-0001-5012-5547
Chien-Te TsengDepartment of Microbiology & Immunology Centers for Biodefense and Emerging Diseases, The University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, Texas 77555, United States.
Thomas D MeekDepartment of Biochemistry and Biophysics, Texas A&M University, 301 Old Main Drive, College Station, Texas 77843, United States.ORCID 0000-0002-1931-8073

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human cathepsin L (hCatL), a lysosomal cysteine protease, facilitates endosomal entry for SARS-CoV-2, making it a critical therapeutic target for COVID-19. Here, we report irreversible tripeptidomimetic inactivators containing a 3-pyridyl alanine residue at the

Indexed as

Antiviral AgentsCathepsin LPeptidomimeticsSARS-CoV-2AnimalsChlorocebus aethiopsCOVID-19EstersHumansMiceStructure-Activity RelationshipVero CellsAntiviral AgentsCathepsin LCTSL protein, humanEstersPeptidomimetics

Identifiers

PMID42014929
PMCPMC13224093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.